Archive
553 articles, sorted by publication time.
The focus of this release is not just another large model, but the linking of protein language models, structure prediction, and a billion-scale structural atlas into a toolchain that researchers can test. It makes the promise of AI-designed proteins more concrete, while also clarifying the distance between experimental validation and clinical translation.
The decision shifts the timing of type 1 diabetes care earlier: no longer only adding insulin after symptoms appear, but giving high-risk people a longer symptom-free period while the immune attack can still be delayed.
Operation TrialBlazer is not just an acceleration pilot, but a set of regulatory signals spanning IND applications, first-in-human dosing, and master protocol trials; it could shorten the path for drugs to enter clinical testing while placing safety boundaries and evidence standards in a brighter spotlight.
As trial designs increasingly depend on molecular markers and patient stratification, diagnostic laboratories are moving from a back-office role to the front line of R&D; but whether data can become faster and fairer recruitment still depends on validation, privacy, and execution details.
Insilico and SK Biopharmaceuticals are extending their collaboration into neuroimmune diseases, but the deal looks more like a staged exam: a small upfront payment buys discovery speed, while the large milestones depend on whether targets, molecules, and clinical evidence can be validated step by step.
The 5,215 clinical drug trials show that China’s biotech R&D has reached scale; but volume itself is not the endpoint. What will truly determine the industry’s position is trial design, data credibility, and patient accessibility.
U.S. regulators are trying to move drug testing onto a faster, more flexible path; but behind the limited information available, the real question is not who runs fastest, but whether speed can be achieved without sacrificing safety and the quality of evidence.
The COPE study compares standard verbal counseling with a pictorial education tool, seeking to answer how information is understood when patients with early-stage breast cancer receive radiation therapy, and whether it can also affect psychological burden.
A government R&D grant moves AI protein design from a platform narrative toward candidate drug validation; the real test is not whether an algorithm can generate molecules, but whether they can pass continuous scrutiny across biology, manufacturing, and clinical safety.
The EU has added AbbVie’s glecaprevir/pibrentasvir as a treatment option for acute hepatitis C, giving adults and children aged 3 and older access to a direct-acting antiviral early in infection; but the approval also underscores that diagnosis and early linkage to care remain key bottlenecks in eliminating hepatitis C.
The acquisition pushes large pharmaceutical companies’ immunology strategies from extending single blockbuster drugs toward the next round of clinical competition in long-acting antibodies, combination designs, and respiratory inflammatory diseases.
IGC Pharma says its AI platform can cut Alzheimer’s drug research time by 90%; against the backdrop of a long-standing high failure rate in neurodegenerative disease R&D, this is an attractive promise, and also a scientific proposition that requires more transparent validation.